Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6930982 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1TSHRMAPK1CASP7 | |
| SCHEMBL6930988 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1TSHRMAPK1CASP7 | |
| SCHEMBL6930984 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1TSHRMAPK1CASP7 | |
| SCHEMBL7527654 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1TSHRMAPK1CASP7 | |
| SCHEMBL13389706 | 0.80 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1TSHRMAPK1CASP7 | |
| SCHEMBL6928048 | 0.80 | TSHR (0.37) | ALDH1A1TSHRMAPK1KDM4E | |
| SCHEMBL6928056 | 0.80 | TSHR (0.37) | ALDH1A1TSHRMAPK1KDM4E | |
| SCHEMBL6928051 | 0.80 | TSHR (0.37) | ALDH1A1TSHRMAPK1KDM4E | |
| SCHEMBL6925024 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1TSHRMAPK1KDM4E | |
| SCHEMBL6925027 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1TSHRMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030027-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A1, GUCY1A2, PDE2A | SMN1; SMN2 1852/4885ALDH1A1 2472/4885TSHR 379/4885 |
| US-10030027-B2 | Soluble guanylate cyclase stimulators | GUCY1A1, GUCY1A2, PDE2A | SMN1; SMN2 1852/4885ALDH1A1 2472/4885TSHR 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.